Coway Co., Ltd

Neuracle Science Co., Ltd.

University-Industry Cooperation Group of Kyung Hee University

Jee Youn Lee

Tae Young Yune

Junho Chung

Young Jo Kim

Bongcheol Kim

Jae Young Seong

Jong Ik Hwang

Eun Bee Cho

Junyeong Jin

Sang Hwa Lee

Sam Young Kim

Tae Hwan Oh

Hyung-Hwan Baik

Hyung Hwan Baik

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof

Water purifier

The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder and central nervous system diseases containing fluoxetine and vitamin C as active ingredients. Specifically, when low concentration of fluoxetine and vitamin C, which did not show any improved effect on the blood-brain barrier disorder and disruption of blood-spinal cord barrier when administered alone, were mixed and co-administered to an animal model with spinal cord injury and transient global ischemia, the co-administration significantly increased the effect of inhibiting the increase of permeability of blood-spinal cord barrier and the effect of inhibiting MMP-9 activation and the effect of alleviating the influx of blood cells in an animal model with spinal cord injury; and the effect of inhibiting the disruption of blood-brain barrier and the effect of recovering memory in a transient global ischemia animal model, compared to the single administration of fluoxetine or vitamin C at the same concentration. The results indicate the synergy effect and the decrease of side effects by the co-administration of the compound at a low concentration, and thus fluoxetine and vitamin C of the present invention can be effectively used as active ingredients for a pharmaceutical composition for the prevention and treatment blood-brain barrier disorder and central nervous system diseases.

Pharmaceutical composition for preventing and treating central nervous system diseases containing fluoxetine and vitamin C as active ingredients

Combined toilet-bidet assembly

Growing community of inventors

Seoul, South Korea

Jee Youn Lee